charged multivesicular body protein 4CGenealiases: SNF7-3 · Shax3 · VPS32C
Q-omics provides the consensus-scored CHMP4C profile across patient tissues and cancer cell-line models. CHMP4C expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CHMP4C is differentially expressed in 11, with the highest sampling consensus in LUAD. Additionally, CHMP4C RNA expression shows 17,765 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, LUAD, and KIRP as cancer lineages where CHMP4C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHMP4C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHMP4C survival associations across molecular data types. CHMP4C RNA expression shows survival associations in the most cancer types (28), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHMP4C RNA expression–survival associations across cancer types. High CHMP4C expression shows unfavorable associations in CESC, PAAD, LGG and LUSC, but favorable associations in KIRC and BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CHMP4C RNA expression.
This table summarizes CHMP4C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in LUAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CHMP4C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHMP4C shows higher tumor expression in LUAD, LIHC, UCEC, BLCA, COAD and BRCA. The LUAD box plot shows higher CHMP4C RNA expression in tumor versus normal tissue (log2 FC = +1.032, t-test p < 0.001).
This table shows molecular features associated with CHMP4C in patient tissues and cancer cell lines. In patient samples, CHMP4C shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, CHMP4C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
